Ethicon expands use of its Mammotome system:
This article was originally published in Clinica
Ethicon Endo-Surgery, a Johnson and Johnson subsidiary, has expanded the use of its Mammotome breast biopsy system to include X-ray-guided stereotactic (ST) procedures. The Mammotome uses a vacuum-assisted, 11-gauge probe for the partial or complete removal of an imaged abnormality. Currently, doctors guide the probe with ultrasound. The Cincinnati, Ohio company expects to launch the system for X-ray ST procedures separately, or as an upgrade to existing Mammotomes, next month.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.